CytoReason news

TEL AVIV, Israel and SEOUL, South Korea, April 12, 2022 /PRNewswire/ -- CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced today the signing of a commercial partnership with Helixrus

TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- CytoReason, a leading developer of computational disease models for efficient drug discovery and development, today announced the extension of its collaboration agreement with Pfizer.

"The extension of our collaboration with CytoReason will build upon our existing data science capabilities, and further enhance our abi

TOKYO and TEL AVIV, Israel, Sept. 30, 2021 /PRNewswire/ -- CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company providing service and

TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each

TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IB